Haematology 2018

JULIET: Study design (Novartis)

CD19 4-1BB, first approved CAR-T (child +TYA) B-ALL

Pts eligible after ≥2 lines chemotherapy, ineligible for or failed auto-SCT

A longer than expected period between enrolment and infusion occurred due to manufacturing delays

a To be completed 2 to 14 days prior to tisagenlecleucel infusion b Infusion conducted on an in- or outpatient basis at investigator discretion